Jin-Fu Xu China

Jin-Fu Xu, MD, PhD is a Professor, Doctoral Supervisor, and Chief Physician at Tongji University, where he also serves as President of Tongji Hospital and Director of the Institute of Respiratory Diseases. He is a leading expert in respiratory medicine and pulmonary infections, with a particular focus on bronchiectasis. Professor Xu is an Expert of the State Council Special Government Allowance and a Distinguished Young Scholar of the National Natural Science Foundation of China. He has received the Outstanding Contribution Award from the Shanghai Municipal Science and Technology Commission. He serves as Chair of the China Bronchiectasis Registry (BE-China), Chair of the Respiratory Disease Branch of the Shanghai Medical Association, and Associate Chair of the Respiratory Disease Branch of the Chinese Medical Association. He is also a Scientific Committee Member of the World Bronchiectasis Conference. Professor Xu is an Associate Chief Editor of Respir Res and an Editorial Board Member of Am J Respir Crit Care Med and Clin Microbiol Infect. He has published over 100 peer-reviewed articles in leading journals, including Lancet Respir Med, Lancet Digit Health, Nat Immunol, Sci Transl Med, Nat Commun, Am J Respir Crit Care Med, Eur Respir J.
Job Title
President, Professor and Chief Physician
Faculty / Department / Division
Department of Respiratory and Critical Care Medicine
Institution / Organisation
Shanghai Tongji Hospital, School of Medicine, Tongji University

21 November 2026, Saturday

Time Session
14:00
15:30
Chee-Shee Chai Chairperson Malaysia
Jung-Kyu Lee Chairperson Republic of Korea
  • Jin-Fu Xu Speaker China
  • Raja Dhar Speaker India
    COPD and bronchiectasis turn up together more often than chance would allow, and patients who have both do badly. In European and Indian cohorts the overlap carries about twice the mortality of either disease alone, along with more admissions and faster loss of lung function. The diagnosis is often made loosely; in the EMBARC registry, one in five patients labelled as COPD had no airflow obstruction. The ROSE criteria now give an objective definition and, importantly for us, accept biomass smoke as an exposure. Guidelines say little directly, so treatment is borrowed from both diseases. In India the overlap is commoner, often follows tuberculosis, and is still managed largely as COPD.
  • Tiew Pei Yee Speaker Singapore
    Chronic airway diseases including COPD, bronchiectasis, and bronchiectasis–COPD overlap (BCO) are biologically heterogeneous conditions. Advances in culture-independent sequencing have transformed our understanding of airway colonization, dysbiosis, and host–microbe interactions in these diseases. This presentation will provide an overview of the airway microbiome landscape across COPD, bronchiectasis, and BCO. I will discuss differences in microbial diversity, dominant pathogen patterns, and the concept of dysbiosis state. The talk will highlight how microbiome configurations relate to inflammation, exacerbation risk, and disease progression, and whether overlapping microbial signatures support shared biological mechanisms in BCO. Emerging approaches including longitudinal profiling, resistome and gut-lung axis will be discussed, with emphasis on how microbiome-informed stratification may guide precision therapy in chronic airway disease. This session aims to synthesize current evidence, identify knowledge gaps, and explore how airway microbiome research can be translated into clinically actionable strategies.
  • Q&A
Ballroom 2, Lower Ground Floor